Democritus University of Thrace (DUTH)
Αξιολόγηση των μικρών μορίων RNA ως βιοδεικτών στην χρόνια Ηπατίτιδα Β
Abstract
dc:descriptionIntroduction: Around 240 million people, worldwide suffer from chronic hepatitis B. In most cases, chronic disease is well controlled due to treatment with nucleoside analogues (NAs), which block viral activity and effectively contribute to stabilizing the disease. However, treatment with NAs can often be interrupted, leading to a flare-up of the disease, with the gradual development of cirrhosis and, in many cases, the onset of hepatocellular carcinoma (HCC). Usually, NAs are a lifelong treatment for chronic hepatitis B patients. However, the oncogenic virulence of the virus often leads patients with CHB to develop cirrhosis and even HCC. Therefore, finding an indirect diagnostic marker for both the evaluation and discontinuation of treatment with NAs may be useful. One marker that can be detected in the circulation and can be used as an indirect marker of HBV transcriptional activity is pregenomic RNA (pgRNA). PgRNA is a template for the expression of reverse transcriptase (RT) and core proteins, while through reverse transcription it gives the negative strand of rcDNA. PgRNA, together with HBV poly and core proteins, is packaged in the endoplasmic reticulum into mature Dane-like virions. Studies using HBV pgRNA as a marker for the evaluation of chronic hepatitis B show that its use can satisfactorily predict the outcome of the disease. Furthermore, the pathophysiology of the liver microenvironment in chronic disease is an area that has not been adequately characterized, leaving gaps in our understanding of the action of innate immunity, while at the same time suggesting that the prevalence of dysfunctional T-lymphocytes is responsible for chronic inflammation. However, it is not only dysfunctional T-lymphocytes that exacerbate fibrosis, but also first-line defense cells, such as neutrophils. Neutrophils secrete chemotactic factors and enter the inflammatory microenvironment through tissue permeation, where they interact with other cells in the hepatic microenvironment. One of these cells is the platelet, which exerts a healing action through thrombosis, but in cases of inflammation, it appears that the phenomenon of immunothrombosis intensifies, causing the proliferation of hepatic stellate cells (HSCs) and worsening fibrosis. Considering the lack of literature on the inflammatory profile of chronic hepatitis B and the contribution of platelets to it, the aim of this PhD thesis is to investigate the transcriptomic profile of patients with chronic hepatitis B and to evaluate it in terms of innate immunity and platelet-neutrophil interactions regarding to the serological marker HBV pgRNA. Materials and Methods: A total of 88 chronic hepatitis B patients negative for HBeAg and undergoing treatment with NAs were examined. The samples collected were plasma, which was tested for all biochemical and virological markers of the virus, as well as for HBV pgRNA using the rt PCR method. The virus genotype was then determined and 8 samples were sequenced. All patients were negative for HBV DNA, 4 of them were positive for HBV pgRNA, while the rest were negative for it. These data were processedusing the bioinformatics tools: TrimGalore, fastp, Hisat2, HTseq, samtools, DESeq2, pheatmap, VennDiagram, and ggplot2. Next, the expression pathways of differentially expressed genes (|log2FC| ≥ 1 and p.adjusted < 0.05) were identified using GSEA performed with the bioinformatics tools: clusterProfiler and the GO (Gene Ontology) and KEGG (Kyoto Encyclopedia for Gene and Genome) databases. The above steps were performed for two different analyses. In the first analysis, chronic patients were compared with each other and with a group of healthy individuals for the presence of HBV pgRNA, while in the second analysis, data were extracted from patients with HBV-related HCC from the GSE57381 study and the chronic condition of the disease was compared with the HCC and the control group. The above analyses revealed common pathways for which experimental setups were organized, such as platelet activation with the serum of chronic patients positive and negative for HBV pgRNA. In addition, platelet-neutrophil interaction was studied, and immunofluorescence and rt PCR procedures were performed on both populations to determine the levels of interleukins IL-1b, IL-17A, the antimicrobial peptide LL-37, and the autophagy proteins BECLIN-1, LC3-B, and P62. Finally, the FIB-4 and PAGE-B indices were determined and evaluated for all samples for the progression of cirrhosis and the risk of developing HCC, respectively. Statistical analysis and the creation of predictive models were performed using SPSS 26.0 and R, where Student's t-test was used for similar variations, and the Mann-Whitney U test was used in the opposite case. Results: The percentage of chronic patients who tested positive for HBV pgRNA was 18.1%. The quantitative levels of HBV pgRNA show a statistically significant positive correlation with the ALT, AST, HBV DNA, HBsAg, and INR indicators, while they are negatively correlated with the duration of treatment. Patients who had been assessed with fibrosis index (Ishak ≥2) were less possible to be detected positive for the HBV pgRNA at the same time compared to patients who was in an early fibrosis stage, according to FIB-4 score. Regarding the first transcriptomic analysis, we identified 916 differentially expressed genes, of which 197 are common to both the HBV pgRNA-positive and HBV pgRNA-negative groups. These common genes appear to be involved in cellular processes such as autophagy and protein folding control, RNA regulation pathways, as well as pathways involved in platelet activation and innate immunity, such as neutrophil degranulation. In the second analysis, 3,215 differentially expressed genes were found, of which 329 are overexpressed in both groups and are common to CHB and HBV-related HCC. GSEA revealed pathways involved in cellular biogenesis processes, such as autophagy, apoptosis inhibition, RNA metabolism, and platelet activation, as well as neutrophil degranulation, which appear to be common with the first analysis. Based on the above pathways, platelets showed an increase in autophagy and their activation, which is consistent with thrombosis activation, as well asinteraction with neutrophils, which appear to follow the development of a pro-inflammatory phenotype. Furthermore, the presence of autophagy in platelets is evident from the increase of LC3-B levels and the antimicrobial peptide LL-37 under the presence of HBV pgRNA. However, the study of LL-37 activity showed neither antimicrobial nor fibrotic activity. The combined study of platelet-neutrophil interaction showed the development of a pro-inflammatory phenotype through high levels of IL-1b in neutrophils. However, while neutrophil elastase expression was observed, its detection was limited to the cytoplasm, resulting in a pro-netotic phenotype with minimal NETs in HBV pgRNA-positive conditions. Furthermore, the absence of IL-17A expression in neutrophils describes the absence of fibrosis, thus indicating a conservative proinflammatory state in the hepatic microenvironment of chronic hepatitis B patients. Conclusions: Despite the study of HBV pgRNA as an indirect marker for the termination of antiviral therapy, it appears that it may also be used as a marker for assessing the fibrotic profile of patients in the chronic phase. The study of the platelet-neutrophil communication axis showed that activated platelets in chronic patients can degranulate reactive factors. The use of neutrophils as mediator cells for platelet action has shown that there is a bidirectional interaction between them. Studying, the course of activation from platelets to neutrophils, it appears that a pro-inflammatory phenotype develops in neutrophils, which is maintained without the presence of fibrotic incidences like the secretion of IL-17A. This reveals a static pro-inflammatory phenotype without fibrotic actions, but ready to trigger them in situations of disease imbalance.As we showed in recent research, this pro-inflammatory phenotype evolves into an inflammatory one in patients with diagnosed cirrhosis, who are characterized by intense NET structures that release IL-1b into the extracellular space, as well as high levels of IL-17A. This confirms the fibrotic action of neutrophils in cirrhosis. Finally, our attempt to combine a viral marker of HBV transcriptional activity with disease progression has paved the way for further study of the platelet-neutrophil axis in chronic disease, but it remains to be determined whether HBV pgRNA is indeed the marker that triggers this intracellular interaction.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Skeva, Aikaterini
- Σκεύα, Αικατερίνη
Subjects
dc:subject × 29- Χρόνια ηπατίτιδα Β
- pgRNA
- NAs
- Αιμοπετάλια
- Ουδετερόφιλα
- NETs
- Ίνωση
- Ανοσοθρόμβωση
- Chronic hepatitis B
- Platelets
- Neutrophils
- Fibrosis
- Immunothrombosis
- Βιολογία
- Φυσικές Επιστήμες
- Βιολογία, άλλοι τομείς
- Βιολογία, διεπιστημονική προσέγγιση
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Μικροβιολογία (ιατρική)
- Κλινική γενετική
- Biological Sciences
- Natural Sciences
- Biology, miscellaneous
- Biology, interdisciplinary
- Clinical Medicine
- Medical and Health Sciences
- Microbiology (medical)
- Clinical Genetics
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61054